NDAORALTABLET
Approved
Sep 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Mechanism of Action
agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic…
Clinical Trials (3)
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
Started Feb 2004
500 enrolled
Osteopenia
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
Started Nov 1994
7,705 enrolled
Osteoporosis, Postmenopausal
EVA: Evista Alendronate Comparison
Osteoporosis